Metsera is on the rise with Novo Nordisk.

Metsera, Inc. (NASDAQ:MTSR) continues to attract investors' attention. On Tuesday, this stock rose to an all-time high following Novо Nordisk’s announcement of increasing its 10 billion dollar acquisition offer for Pfizer Inc..

During intraday trading, Metsera reached a new 52-week high of 74.24 dollars and closed the day at 73.18 dollars, reflecting a 20.50% increase.

Earlier in the day, Novо Nordisk announced that it had raised its offer for Metsera to 10 billion dollars. Metsera noted that Pfizer’s 7 billion dollar offer was “superior.” Specifically, Pfizer had received approval for a merger plan with Metsera last month.

In Novо Nordisk’s updated offer, Metsera, Inc.’s total common stock will be purchased at 62.20 dollars per share, and additional value rights of 24 dollars will be provided based on certain clinical and regulatory successes.

On Tuesday, Pfizer filed two lawsuits against Novо Nordisk and the controlling shareholders of Metsera. The lawsuit claimed that Novо Nordisk engaged in “anti-competitive behavior” and acted to maintain its dominance in the GLP-1 market.

Pfizer stated that it plans to take all necessary measures to prevent the progression of Novо Nordisk’s anti-competitive proposed transaction.

We acknowledge the potential of MTSR as an investment, but believe that some artificial intelligence (AI) stocks offer greater promises of higher returns and limited downside risk. If you are looking for an extremely undervalued AI stock that stands to benefit significantly from Trump tariffs and localization, check out our free report on the best short-term AI stock.